The presentation of data at a major conference like the SNO Annual Meeting can increase visibility and credibility for Plus Therapeutics' CNSide CSF Assay. The assay's ability to identify actionable mutations and biomarkers is significant for treatment advancements, likely leading to positive investor sentiment and a potential short-term stock price increase.